- Home
- IMMP vs SLP Comparison
IMMP vs SLP Comparison
Compare IMMP & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- SLP
- Stock Information
- Founded
- IMMP 1987
- SLP 1996
- Country
- IMMP Australia
- SLP United States
- Employees
- IMMP N/A
- SLP N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- SLP EDP Services
- Sector
- IMMP Health Care
- SLP Technology
- Exchange
- IMMP Nasdaq
- SLP Nasdaq
- Market Cap
- IMMP 251.8M
- SLP 282.4M
- IPO Year
- IMMP N/A
- SLP 1997
- Fundamental
- Price
- IMMP $1.68
- SLP $15.93
- Analyst Decision
- IMMP Buy
- SLP Buy
- Analyst Count
- IMMP 1
- SLP 7
- Target Price
- IMMP $7.00
- SLP $29.50
- AVG Volume (30 Days)
- IMMP 88.5K
- SLP 445.5K
- Earning Date
- IMMP 10-21-2025
- SLP 10-22-2025
- Dividend Yield
- IMMP N/A
- SLP N/A
- EPS Growth
- IMMP N/A
- SLP N/A
- EPS
- IMMP N/A
- SLP N/A
- Revenue
- IMMP $3,306,742.00
- SLP $80,383,000.00
- Revenue This Year
- IMMP N/A
- SLP $12.75
- Revenue Next Year
- IMMP $725.37
- SLP $3.06
- P/E Ratio
- IMMP N/A
- SLP N/A
- Revenue Growth
- IMMP 31.28
- SLP 20.01
- 52 Week Low
- IMMP $1.32
- SLP $12.39
- 52 Week High
- IMMP $2.71
- SLP $37.67
- Technical
- Relative Strength Index (RSI)
- IMMP 50.03
- SLP 64.50
- Support Level
- IMMP $1.60
- SLP $13.78
- Resistance Level
- IMMP $1.76
- SLP $16.27
- Average True Range (ATR)
- IMMP 0.06
- SLP 0.66
- MACD
- IMMP 0.01
- SLP 0.22
- Stochastic Oscillator
- IMMP 52.94
- SLP 86.96
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.